Phospho-eIF4B (Ser406)抗体;Phospho-eIF4B (Ser406) Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of Phospho-eIF4B (Ser406) in mouse heart lysates using Phospho-eIF4B (Ser406) antibody.    

  
  

•  

   

     Western blot analysis of eIF4B (Phospho-Ser406) in A549, HL-60, U2OS, C6 lysates using eIF4B (Phospho-Ser406) antibody.    

  
  

•  

   

     Immunohistochemistry analysis of paraffin-embedded Human lung cancer using eIF4B (Phospho-Ser406) antibody. High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.    

  
  

The Phospho-eIF4B (Ser406) antibody is a specialized tool used to detect the phosphorylation status of eukaryotic translation initiation factor 4B (eIF4B) at serine residue 406. eIF4B is a critical regulatory protein in mRNA translation initiation, promoting ribosome recruitment to mRNA by facilitating the helicase activity of eIF4A and stabilizing interactions between the 43S preinitiation complex and mRNA. Phosphorylation at Ser406 is a key post-translational modification that enhances eIF4B's activity, particularly under stress conditions or growth factor stimulation. This modification is primarily mediated by the mTORC1 (mechanistic target of rapamycin complex 1) and MAPK (mitogen-activated protein kinase) signaling pathways, linking translational control to cellular proliferation, survival, and stress responses.

The Phospho-eIF4B (Ser406) antibody is widely employed in research to study translational regulation in contexts such as cancer, metabolic disorders, and cellular stress. It enables the detection of activated eIF4B in techniques like Western blotting, immunofluorescence, and immunohistochemistry. By assessing Ser406 phosphorylation, researchers gain insights into mTORC1/MAPK pathway activity and their roles in diseases. Validation of this antibody typically includes testing in knockout models or phosphatase-treated samples to confirm specificity. Its applications extend to preclinical studies targeting translation machinery for therapeutic interventions, particularly in cancers with dysregulated mTOR or MAPK signaling.